Literature DB >> 1829098

Response to steroid suppression in major depression resistant to antidepressant therapy.

B E Murphy1, V Dhar, A M Ghadirian, G Chouinard, R Keller.   

Abstract

Because of the similarities in the psychiatric symptoms of Cushing's syndrome and those of major depression, and because the former generally remits when the hyperadrenalism is alleviated, an open clinical trial of the effect of steroid suppression in major depression was undertaken. Ten patients satisfying the DSM-III-R criteria for major depression, and classified as treatment-resistant, were included. Eight patients completed the study, which consisted of discontinuation of other psychotropic drugs and 2 months' treatment with one or more steroid suppressive agent (aminoglutethimide, ketoconazole and/or metyrapone). Six were classified as responders, and two as partial responders. In six, the improvement has been sustained for longer than 5 months after withdrawing the drugs. Side effects were mild to moderate. These results provide some evidence that steroids are involved in the maintenance of major depression, and that their suppression may lead to a readjustment of the hypothalamic-pituitary-adrenal axis with remission of the depression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829098

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  15 in total

1.  Enhancement of serotonin uptake by cortisol: a possible link between stress and depression.

Authors:  G E Tafet; M Toister-Achituv; M Shinitzky
Journal:  Cogn Affect Behav Neurosci       Date:  2001-03       Impact factor: 3.282

Review 2.  [New developments in pharmacotherapy of depression].

Authors:  R Rupprecht; Th C Baghai; H-J Möller
Journal:  Nervenarzt       Date:  2003-05-10       Impact factor: 1.214

3.  Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats.

Authors:  Yoshihisa Kitamura; Takahiko Yagi; Kouhei Kitagawa; Kazuaki Shinomiya; Hiromu Kawasaki; Masato Asanuma; Yutaka Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-06       Impact factor: 3.000

Review 4.  Hippocampal damage mediated by corticosteroids--a neuropsychiatric research challenge.

Authors:  C Höschl; T Hajek
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

5.  Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.

Authors:  B E Murphy; D Filipini; A M Ghadirian
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

Review 6.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

7.  Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats.

Authors:  Kouhei Kitagawa; Yoshihisa Kitamura; Toshiaki Miyazaki; Junya Miyaoka; Hiromu Kawasaki; Masato Asanuma; Toshiaki Sendo; Yutaka Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-03-10       Impact factor: 3.000

Review 8.  Effects of adrenal cortex hormones on limbic structures: some experimental and clinical correlations related to depression.

Authors:  B Dubrovsky
Journal:  J Psychiatry Neurosci       Date:  1993-01       Impact factor: 6.186

9.  Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine.

Authors:  Cornelius Schüle; Thomas Baghai; Peter Zwanzger; Robin Ella; Daniela Eser; Frank Padberg; Hans-Jürgen Möller; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2003-01-28       Impact factor: 4.530

10.  Dexamethasone target sites in the central nervous system and their potential relevance to mental illness.

Authors:  M K Birmingham; M Sar; W E Stumpf
Journal:  Cell Mol Neurobiol       Date:  1993-08       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.